Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/194643
Genomics and epigenomics of substance use disorders: An introduction
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Substance use disorders (SUD) are common conditions around theworld, with important health and societal impacts, particularly inthe burden of disease (disability-adjusted life years) (Whiteford, Fer-rari, Degenhardt, Feigin, & Vos, 2015). The Global Burden of DiseaseStudy estimated the global number of cases for SUD for several sub-stances as follows: 94.8 million for alcohol, 17.2 million for amphet-amine, 15.5 million for opioids, and 13.1 million for cannabis(Whiteford, 2015). In the United States, the lifetime and 12-monthprevalences of SUD were 9.9% and 3.9%, respectively (Grantet al., 2016). In addition, polysubstance use is an important challengein the field of addiction research (Whiteford et al., 2015).
Matèries
Matèries (anglès)
Citació
Citació
CORMAND RIFÀ, Bru, et al. Genomics and epigenomics of substance use disorders: An introduction. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2021. Vol. 186, num. 3, pags. 125-127. ISSN 1552-4841. [consulted: 26 of May of 2026]. Available at: https://hdl.handle.net/2445/194643